Search academic texts

Head: Lyalkin Serhii A.. Improving the results of conservative treatment of breast cancer patients with low or negative HER2/neu status based on optimization and individualization of therapy methods. (popup.stage: ). National Cancer Institute. № 0224U031503

Tetiana Y. Tarasenko. Optimization of hormone therapy with aromatase inhibitors in patients with metastatic luminal (HER2-negative) breast cancer and its correlation with polymorphisms of estrogen receptor gene : Доктор філософії : spec.. 222 - Медицина : presented. 2023-11-16; popup.evolution: .; Bogomolets National Medical University. – Київ, 0823U100818.

Head: Syvak Lubov А.. Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression.. (popup.stage: ). National Cancer Institute. № 0223U002359

Head: Syvak Lubov А.. Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression.. (popup.stage: ). National Cancer Institute. № 0222U003718

Head: Syvak Lubov А.. To optimize treatment in patients with metastatic breast cancer molecular subtypes adverse prognostic. (popup.stage: ). National Cancer Institute. № 0220U102648